U.S. Markets closed

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
232.54+7.08 (+3.14%)
At close: 1:00PM EST
Sign in to post a message.
  • J
    Jason Gustavo Esperado
    $AFMD conversation
    $AFMD should be currently worth at least double/triple to that of $MRTX considering AFM24 is independent of EGFR signaling and mutational status and not limited to just KRAS mutations.
  • A
    Headlines from this morning's MRTX Press Release are very encouraging. See the rest of the release for details.
    To me, this could get MRTX shares well over $225 in the near term....and higher thereafter as word spreads about the possible implications for this set of drug treatments for several cancers.

    Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
    Sun, October 25, 2020, 10:45 AM EDT

    - 45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients with advanced NSCLC

    - Median duration of treatment >8 months with 50% of patients and 83% of responders still on treatment in the Phase 1/1b monotherapy cohort in patients with advanced NSCLC

    - Well-tolerated safety profile across monotherapy and combination trials

    - Initial preclinical data for MRTX1133, the Company's potential first-in-class KRAS G12D selective inhibitor, demonstrate significant tumor regression in mutant animal models; IND filing planned for 1H 2021
  • S
    Just heard that MRTX got alerted at (http://webstock.today). I hope it pushes us higher!
  • A
    MRTX just announced an offering of less than 1% of total shares outstanding. Investment bankers dropped share price to accommodate demand for the deal....which was probably already pre-sold to meet demand of institutional guys who wanted in, especially after yesterday's data announcement. We should be back over $200 soon.....
  • B
    ETTX = MEGA Buying Opp today on the dip ...TWO Big Phase 3 readouts very soon !!!!

    ETTX= MC $65 M / Cash $50 M / 2 BIG Phase 3 Drugs with readouts expected next Quarter / Astrazeneca Spin-Off / MASSIVE insider & Institutional Ownership = A potential 10++ Bagger

  • A
    Lots of new and exciting expansive data being released and discussed....if you own MRTX or have an interest, you should listen to today's presentation.
  • A
    Deal priced at $202....all sides win with aggressive pricing.
  • P
    Wow Big offering! Watching this one, I'll grab some shares if it sells off.
  • A
    My guess is that the deal has closed and been priced pretty close to $195, thereby affording all participation institutions a nice first-day bump. I'm sure we'll soon be informed.
  • W
    $AGEN conversation
    $mrtx was under 3, 3 years ago. Now it's over 200 on good kras data for lung cancer. I had similar dreams stock price dreams for $agen when I made my first purchase in 2017. Now I just dream of $agen staying above $4 lol. God dammit.
  • A
    We blew right past $160 which was my "target" in my most recent post. It looks like we may be "in play" as we obviously have very desirable pipeline assets....we'll see..........
  • A
    We hit the second century mark ($200) in fairly short time. It now falls to the data to get us to the third century mark....I'm optimistic.
  • P
    Do they wholly own their pipeline or licensed it out?
  • b
    I started following "lionstock-aletrs” (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • A
    First take on the MRTX data dump today.

    It's still early but, based upon a very small patient sample, we would appear to be equal to, or perhaps better than AMGN's KRAS drug which, to me, is a win as it says we're in the game in a serious way.
    Still, MRTX has more work to do...and subsequent data for both MRTX and AMGN could move the needle meaningfully in our favor (or against us if future reads do not confirm our preliminary data). AMGN, if I'm not mistaken, has been given a fast-track pathway to approval....and we also should be given similar concessions....as the more robust data for both companies unfolds, one may be a more clear winner....but the data confirmations are patient-dependent and will read out several quarters from now.
    I like our odds. We're the little engine that could and our market cap vs AMGN in KRAS-related indications/solutions is minuscule and, with further improvement in our data, our upside will be quite large.
    Someone posted $200 as a price target. That may eventually happen but, in the near-term, I'm happy to be "in play" with our data and will await next readouts....who knows how far we may go...but I have a feeling it's a long way....right now, $200 looks good. :-)
  • t
    With the options activity I think things will be strong in the coming weeks, In the meantime I am watching this one too. https://alldaytrading.market/StockFeature
    Two of the fastest growing industries right now in the United States are on-demand technology and cannabis. These two industries are at the epicenter of growth and investors aren’t being shy about their appetite for companies in these arenas. But one
    Two of the fastest growing industries right now in the United States are on-demand technology and cannabis. These two industries are at the epicenter of growth and investors aren’t being shy about their appetite for companies in these arenas. But one
  • p
    SunTrust just released a note stating that a series of strong data catalysts&disruptive medicines being commercialized or entering the clinic they recommend investors being overweight biotech. Their recommendations are:


    Our time is coming - just be patient.
  • s
    Don’t understand no revenue no big or good news yet it is over $100
  • A
    Keep in mind that MRTX is a very, very "thin" stock which means that even relatively small buy and sell orders can trigger outsized moves. When you back out insider and institutional shareholdings, there are very few shares (relatively speaking) in the float. So we have large ups and downs on an almost daily basis.
  • K
    It was a 2 penny per share stock in 2013 when it did reverse stock split (50/1).